NCT02095990

Efficacy and Safety of a 4% Hydroquinone Cream for the Treatment of Melasma

Efficacy and Safety of a 4% Hydroquinone Cream (Melanoderm 4%) for the Treatment of Melasma: a Randomized Controlled Split-face Study

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 17 (actual)
• Sponsor: Mesoestetic Pharma Group S.L. · Industry
• Sex: Female
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

To assess the ability of a new 4% Hydroquinone formulation (Melanoderm 4% Crema) to reduce melasma on the face, using a split-face randomization design, evaluating the MASI Score from baseline to week 4 and week 8, in both half-faces receiving active treatment vs. placebo. To assess the tolerance of a new 4% Hydroquinone formulation (Melanoderm 4% Crema) on the face. To assess patients' satisfaction regarding Melanoderm 4% Crema after 8 weeks.

Conditions

• Facial Melasma

Interventions

Type	Name	Description
DRUG	Hydroquinone
DRUG	Placebo

Timeline

• Start date: 2014-03-01
• Primary completion: 2014-08-01
• Completion: 2014-08-01
• First posted: 2014-03-26
• Last updated: 2019-09-30

Locations

1 site across 1 country: Spain